riluzole has been researched along with Osteosarcoma in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our lab has previously demonstrated Riluzole to be an effective drug in inhibiting proliferation and inducing apoptosis in both human and mouse osteosarcoma." | 8.02 | Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase. ( Azeem, SM; Blyufer, A; Cecilio, L; ChandThakuri, S; Chowdhury, Y; Hasnat, R; Huang, YQ; Lhamo, S; Mahajan, SS; Raghubir, M; Rahman, CN; Tam, C; Tariq, I; Wong, L; Yan, S; Zhagui, R, 2021) |
| "In human osteosarcoma MG63 cells, the effect of the neuroprotective drug riluzole on the intracellular Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2." | 7.71 | Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. ( Chang, HT; Huang, JK; Jan, CR; Jiann, BP; Lu, YC, 2002) |
| "Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals." | 5.56 | Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. ( Fang, J; Mahajan, SS; Matsui, H; Raghubir, M; Rahman, CN, 2020) |
| "Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling." | 5.46 | Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. ( Ait Taouit, L; Basu-Roy, U; Gulzar, H; Houssou, M; Jaikaran, T; Kozlitina, K; Liao, S; Mahajan, SS; Mansukhani, A; Ruiz, Y; Schvarts, Y; Yelskaya, Z, 2017) |
| "Our lab has previously demonstrated Riluzole to be an effective drug in inhibiting proliferation and inducing apoptosis in both human and mouse osteosarcoma." | 4.02 | Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase. ( Azeem, SM; Blyufer, A; Cecilio, L; ChandThakuri, S; Chowdhury, Y; Hasnat, R; Huang, YQ; Lhamo, S; Mahajan, SS; Raghubir, M; Rahman, CN; Tam, C; Tariq, I; Wong, L; Yan, S; Zhagui, R, 2021) |
| "In human osteosarcoma MG63 cells, the effect of the neuroprotective drug riluzole on the intracellular Ca(2+) concentration ([Ca(2+)](i)) was measured using fura-2." | 3.71 | Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells. ( Chang, HT; Huang, JK; Jan, CR; Jiann, BP; Lu, YC, 2002) |
| "Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals." | 1.56 | Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. ( Fang, J; Mahajan, SS; Matsui, H; Raghubir, M; Rahman, CN, 2020) |
| "Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential for the treatment of osteosarcoma exhibiting autocrine glutamate signaling." | 1.46 | Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. ( Ait Taouit, L; Basu-Roy, U; Gulzar, H; Houssou, M; Jaikaran, T; Kozlitina, K; Liao, S; Mahajan, SS; Mansukhani, A; Ruiz, Y; Schvarts, Y; Yelskaya, Z, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raghubir, M | 2 |
| Azeem, SM | 1 |
| Hasnat, R | 1 |
| Rahman, CN | 2 |
| Wong, L | 1 |
| Yan, S | 1 |
| Huang, YQ | 1 |
| Zhagui, R | 1 |
| Blyufer, A | 1 |
| Tariq, I | 1 |
| Tam, C | 1 |
| Lhamo, S | 1 |
| Cecilio, L | 1 |
| Chowdhury, Y | 1 |
| ChandThakuri, S | 1 |
| Mahajan, SS | 3 |
| Fang, J | 1 |
| Matsui, H | 1 |
| Liao, S | 1 |
| Ruiz, Y | 1 |
| Gulzar, H | 1 |
| Yelskaya, Z | 1 |
| Ait Taouit, L | 1 |
| Houssou, M | 1 |
| Jaikaran, T | 1 |
| Schvarts, Y | 1 |
| Kozlitina, K | 1 |
| Basu-Roy, U | 1 |
| Mansukhani, A | 1 |
| Jan, CR | 1 |
| Lu, YC | 1 |
| Jiann, BP | 1 |
| Chang, HT | 1 |
| Huang, JK | 1 |
4 other studies available for riluzole and Osteosarcoma
| Article | Year |
|---|---|
Riluzole-induced apoptosis in osteosarcoma is mediated through Yes-associated protein upon phosphorylation by c-Abl Kinase.
Topics: Apoptosis; bcl-2-Associated X Protein; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival | 2021 |
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice.
Topics: Animals; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Compo | 2020 |
Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cel | 2017 |
Effect of riluzole on cytosolic Ca2+ increase in human osteosarcoma cells.
Topics: Calcium; Cytosol; Dose-Response Relationship, Drug; Humans; Osteosarcoma; Riluzole; Tumor Cells, Cul | 2002 |